Video: New Insights Link Low HDL-Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at Goal for LDL-C...(atients with type 2 diabetes.(4) ....),Health

Atherogenic Dyslipidemia and Residual Vascular Risk

Atherogenic dyslipidemia is characterized by elevated TG and low levels of HDL-C.

In the past three decades in the U.S., while the prevalence of abnormal levels of LDL-C has decreased, the prevalence of combined abnormal TG (greater than or equal to 150 mg/dL) and HDL-C (<40 mg/dL) has doubled and the prevalence of elevated TG (greater than or equal to 150 mg/dL) has increased five-fold.(5) Elevated TG (>150 mg/dL) is also common, affecting about 50 percent of adults with prior CVD.(6)

Atherogenic dyslipidemia contributes to the increased risk of macrovascular events such as myocardial infarction and stroke, and may be implicated in microvascular complications such as diabetic eye, kidney and lower limb disease.(7)

• Among patients achieving LDL-C <70 mg/dL with a statin, CVD risk is almost 60 percent greater for patients with TG >200 mg/dL(8)
• In patients achieving LDL-C <70 mg/dL with a statin, CV risk was higher in patients with a low HDL-C (HDL-C <37 mg/dL vs. those with a HDL-C >55 mg/dL)(9)
  

The mission of R3i

To reduce the significant residual risk of macrovascular events and microvascular complications which persists in most patients despite current standards of care including achievement of low density lipoprotein goal and intensive control of blood pressure and blood glucose.

R3i board of trustees

Professor Jean-Charles Fruchart, President

Institut Pasteur de Lille Universite, Lille2, Lille, France

Professor Frank Sacks, Vice-President

Harvard School of Public Health

Harvard Medical School, Boston, USA

Professor Michel P. Hermans, General Secretary

Cliniques Universi
'/>"/>